Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 8/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970146 | 0.89 | PPARD (0.46) | SCN3APPARAPPARGPPARD | |
| SCHEMBL3963800 | 0.84 | CYP11B1 (0.42) | CYP11B1CYP11B2SCN3APPARAPPARG | |
| SCHEMBL3967329 | 0.82 | CYP11B1 (0.44) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3965811 | 0.82 | CYP11B1 (0.40) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3966953 | 0.81 | PPARD (0.44) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3961784 | 0.80 | CYP11B1 (0.42) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3964889 | 0.80 | CYP11B1 (0.38) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3964888 | 0.79 | CYP11B1 (0.41) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3969607 | 0.79 | CYP11B1 (0.41) | CYP11B1CYP11B2PPARAPPARGPPARD | |
| SCHEMBL3958856 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | CYP11B1 44/4885CYP11B2 47/4885SCN3A 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.